机构：[1]Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China[2]Department of Women’s Health, University Hospitals of Tuebingen, Tuebingen, Germany[3]Department of Obstetrics and Gynecology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China临床科室妇产科首都医科大学附属安贞医院
Objective To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance. Methods A total of 240 PCOS women were randomly allocated to receive Diane-35 alone (D group), Diane-35 plus orlistat (DO group), Diane-35 plus metformin (DM group), or Diane-35 plus orlistat plus metformin (DOM group). Serum TT, DHEA-S, androstenedione, SHBG, FT, FAI, body fat, and body fat percentage were assessed at baseline and after 12 weeks of treatment. Results Significant changes in serum TT, SHBG, and FAI were observed in all treatment groups compared with baseline. DHEA-S and androstenedione significantly decreased in the DO, DM, and DOM groups after treatment. FT only significantly decreased in the DOM group. Body fat and body fat percentage significantly decreased in the DO and DOM groups. Compared with the D group, DHEA-S significantly decreased in the DO, DM, and DOM groups (F = 4.081, p = 0.008); SHBG significantly increased in the DOM group (F = 3.019, p = 0.031); and FAI significantly decreased in the DO group (chi(2) = 12.578, p = 0.006). There were significant differences between groups in body fat percentage (chi(2) = 23.590, p < 0.001). Side-effects were less with orlistat than metformin. Conclusions Diane-35 in combination with orlistat or metformin is more effective in reducing androgen than Diane-35 alone. Orlistat is more effective in reducing body fat percentage than metformin. In addition, orlistat has mild side-effects and is better tolerated compared with metformin.
基金：
Capital Characteristic Clinic Project of China [Z161100000516143]; Beijing Capital Foundation for Medical Science Development and Research [2016-2-2113]; Clinical Technique Innovation Project of Beijing Municipal Administration of Hospitals [XMLX201710]; Beijing Municipality Health Technology High-level Talent [2014-2-016]; Foreign technical and administrative talent introduction project, State Administration of Foreign Experts Affairs, the P. R. of China [20171100004]
第一作者机构：[1]Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China[2]Department of Women’s Health, University Hospitals of Tuebingen, Tuebingen, Germany
通讯作者：
通讯机构：[1]Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China[2]Department of Women’s Health, University Hospitals of Tuebingen, Tuebingen, Germany
推荐引用方式(GB/T 7714)：
Ruan Xiangyan,Song Jinghua,Gu Muqing,et al.Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients[J].ARCHIVES OF GYNECOLOGY AND OBSTETRICS.2018,297(6):1557-1563.doi:10.1007/s00404-018-4762-0.
APA：
Ruan, Xiangyan,Song, Jinghua,Gu, Muqing,Wang, Lijuan,Wang, Husheng&Mueck, Alfred O..(2018).Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.ARCHIVES OF GYNECOLOGY AND OBSTETRICS,297,(6)
MLA：
Ruan, Xiangyan,et al."Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients".ARCHIVES OF GYNECOLOGY AND OBSTETRICS 297..6(2018):1557-1563
